USA Financial Formulas Takes Position in Astrazeneca Plc $AZN

USA Financial Formulas purchased a new stake in Astrazeneca Plc (NYSE:AZN) in the fourth quarter, Holdings Channel reports. The firm purchased 10,063 shares of the company’s stock, valued at approximately $925,000.

Several other institutional investors also recently bought and sold shares of AZN. Brighton Jones LLC grew its position in shares of Astrazeneca by 93.2% during the 4th quarter. Brighton Jones LLC now owns 5,782 shares of the company’s stock worth $379,000 after buying an additional 2,789 shares in the last quarter. AQR Capital Management LLC lifted its stake in Astrazeneca by 45.3% in the first quarter. AQR Capital Management LLC now owns 37,501 shares of the company’s stock worth $2,756,000 after acquiring an additional 11,690 shares during the period. Rhumbline Advisers grew its holdings in Astrazeneca by 3.3% during the 2nd quarter. Rhumbline Advisers now owns 29,064 shares of the company’s stock worth $2,031,000 after acquiring an additional 922 shares in the last quarter. CreativeOne Wealth LLC increased its position in Astrazeneca by 3.4% during the 2nd quarter. CreativeOne Wealth LLC now owns 5,561 shares of the company’s stock valued at $389,000 after purchasing an additional 183 shares during the period. Finally, J.W. Cole Advisors Inc. raised its holdings in shares of Astrazeneca by 3.3% in the 2nd quarter. J.W. Cole Advisors Inc. now owns 20,981 shares of the company’s stock valued at $1,466,000 after purchasing an additional 663 shares in the last quarter. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts recently issued reports on AZN shares. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Astrazeneca in a report on Friday, February 6th. Barclays reissued an “overweight” rating on shares of Astrazeneca in a research report on Tuesday, January 6th. Wall Street Zen upgraded Astrazeneca from a “hold” rating to a “buy” rating in a research note on Friday, March 20th. Citigroup started coverage on Astrazeneca in a research report on Tuesday, January 27th. They set a “buy” rating on the stock. Finally, Guggenheim reiterated a “buy” rating on shares of Astrazeneca in a research note on Wednesday, December 3rd. Nine analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $95.75.

Astrazeneca Stock Up 2.8%

Shares of AZN stock opened at $188.57 on Friday. Astrazeneca Plc has a 12-month low of $122.48 and a 12-month high of $212.71. The company has a debt-to-equity ratio of 0.51, a quick ratio of 0.72 and a current ratio of 0.94. The firm has a market cap of $292.45 billion, a PE ratio of 28.79, a price-to-earnings-growth ratio of 1.42 and a beta of 0.32.

Astrazeneca Announces Dividend

The firm also recently declared a dividend, which was paid on Monday, March 23rd. Shareholders of record on Friday, February 20th were paid a $1.595 dividend. The ex-dividend date was Friday, February 20th. This represents a yield of 156.0%. Astrazeneca’s dividend payout ratio (DPR) is 66.26%.

Astrazeneca News Roundup

Here are the key news stories impacting Astrazeneca this week:

• Positive Sentiment: Late‑stage trial win — Tozorakimab met primary goals in two pivotal trials, reducing chronic obstructive pulmonary disease flare‑ups versus placebo; the surprise positive readout is driving optimism about near‑term commercialization potential and pipeline momentum. AstraZeneca stock jumps 4% after surprise trial win for lung disease drug where rivals have failed
• Positive Sentiment: Regulatory and commercial implications — Reuters and other outlets highlight the meaningful reduction in flare‑ups and the significance of a successful phase III outcome for a disease area where competitors have struggled, which increases the drug’s value on AstraZeneca’s roadmap. AstraZeneca drug reduces COPD flare ups in late-stage trials
• Positive Sentiment: Clinical confirmation across endpoints — The Wall Street Journal and other reports emphasize that the trials hit their primary endpoints by lowering symptom worsening rates, reinforcing confidence in the data’s robustness and the potential for label and payer discussions. AstraZeneca Lung Disease Drug Candidate Hits Goals in Late-Stage Trials
• Neutral Sentiment: Stock movement vs. market — Coverage notes AZN advanced while broader markets were down, indicating the move is company‑specific (trial news/pipeline) rather than market driven. Astrazeneca (AZN) Advances While Market Declines: Some Information for Investors
• Neutral Sentiment: Analyst positioning — AstraZeneca has a consensus analyst rating of “Moderate Buy,” which supports the stock’s upside but does not by itself explain today’s move; analyst views may follow as investigators and investors digest full data and commercial assumptions. Astrazeneca Plc (NYSE:AZN) Receives Consensus Rating of “Moderate Buy” from Analysts

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.